DOCSLIB.ORG

KDM8, a H3k36me2 Histone Demethylase That Acts in the Cyclin A1 Coding Region to Regulate Cancer Cell Proliferation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
KDM8, a H3k36me2 Histone Demethylase That Acts in the Cyclin A1 Coding Region to Regulate Cancer Cell Proliferation KDM8, a H3K36me2 histone demethylase that acts in the cyclin A1 coding region to regulate cancer cell proliferation Datsun A. Hsiaa, Clifford G. Teppera, Mamata R. Pochampallia, Elaine Y. C. Hsiaa, Chie Izumiyaa, Steve B. Huertaa, Michael E. Wrightb, Hong-Wu Chena, Hsing-Jien Kunga,1, and Yoshihiro Izumiyaa,c,1 aDepartment of Biochemistry and Molecular Medicine, University of California Davis School of Medicine, University of California Davis Cancer Center, Sacramento, CA 95817; bDepartment of Molecular Physiology and Biophysics, University of Iowa, Iowa City, IA 52242; and cDepartment of Dermatology, University of California Davis School of Medicine, University of California Davis Cancer Center, Sacramento, CA 95817 Edited* by James C. Wang, Harvard University, Cambridge, MA, and approved April 21, 2010 (received for review January 13, 2010) Localized chromatin modifications of histone tails play an impor- Results tant role in regulating gene transcription, and aberration of these JMJD5/KDM8 Is a H3K36me2 Demethylase. Our initial experiments processes leads to carcinogenesis. Methylated histone lysine resi- explored the potential histone demethylase activity of KDM8. To this dues, a key player in chromatin remodeling, are demethylated by end, WT KDM8 and KDM8-H321A (JmjC domain mutant)– the JmjC class of enzymes. Here we show that JMJD5 (now renamed inducible cell lines were generated using MCF7 breast cancer cells. KDM8), a JmjC family member, demethylates H3K36me2 and is By analogy to other JmjC histone demethylases, the H321A mutation required for cell cycle progression. Chromatin immunoprecipitation is predicted to knock out KDM8 enzymatic activity through disrup- assays applied to human genome tiling arrays in conjunction with tion of its ability to bind the ferrous ion and thus its putative deme- RNA microarray revealed that KDM8 occupies the coding region of thylase activity. Immunofluorescence as well as immunoblotting as- cyclin A1 and directly regulates transcription. Mechanistic analyses says were performed using methylation-specific antibodies to screen showed that KDM8 functioned as a transcriptional activator by for probable histone residue substrates. Immunofluorescence assay inhibiting HDAC recruitment via demethylation of H3K36me2, an revealed that 80% of KDM8-overexpressing cells exhibited a sub- CELL BIOLOGY epigenetic repressive mark. Tumor array experiments revealed stantial decrease in H3K36me2 staining. In contrast, a significant KDM8 is overexpressed in several types of cancer. In addition, increase of H3K36me2 methylation was detected in approximately loss-of-function studies in MCF7 cells leads to cell cycle arrest. These 60% of KDM8-H321A–expressing cells (Figs. 1 A and B). The result studies identified KDM8 as an important cell cycle regulator. also indicates that KDM8-H321A may act as a dominant negative for H3K36me2 demethylation. Significantly, the overall level of neither breast cancer | epigenetics | JmjC | cell cycle | transcription H3K36me1 nor H3K36me3 methylation was altered, indicating the specificity of the enzyme. Immunoblot analysis of acid-extracted egulation of gene expression through posttranslational modi- histones from the inducible cell lines further verified that over- Rfication of the core histones has increasingly shown to be of expression of KDM8, but not the enzymatically inactive H321A great importance, particularly in a cancer setting. Among the mul- mutant, demethylated H3K36me2 in vivo (Fig. 1C). The in vivo tiple types of histone modifications, histone methylation, once con- specificity of KDM8 toward H3K36me2 was further demonstrated by sidered irreversible, has quickly emerged to become a key epigenetic blotting with other commercially available antibodies against meth- mark in regulating many critical cellular functions. The recent dis- ylated lysine or arginines of histones H3 and H4, including anti- covery of histone demethylases has shed light on the reversibility of H3K36me1 and anti-H3K36me3; none revealed a decreased in- C A this chromatin mark and its effects on gene expression. Studies ex- tensity in the KDM8-overexpressing cell line (Fig. 1 and Fig. S1 ). ploring the JmjC (Jumonji C domain)–containing proteins, a new- Additionally, MS analysis using a truncated recombinant KDM8 protein consisting of the JmjC domain (101-C) or its equivalent class of histone demethylases (1–4), primarily identified their H321A mutant with H3K36me2 peptide was performed. These enzymatic activity at the promoters of specific target genes (5, 6). results revealed that WT 101-C truncated protein demethylates The JmjC domain–containing gene family encodes a wide range H3K36me2 directly, as indicated by the 14-Da shift from the origi- of the eukaryotic genome and is conserved in species spanning fi nal peptide mass. In contrast, no mass shift was observed when cat- from yeast to humans. Currently, most family members classi ed alytically inactive KDM8 101-C H321A mutant was used (Fig. 1D). as histone demethylases contain known histone-binding domains such as PHD and Tudor domains (7). JMJD5 (renamed KDM8) JMJD5/KDM8 Expression Is Critical for MCF7 Cancer Cell Proliferation. is a member of this extensive protein family that lacks recog- The biological functions and clinical significance of KDM8 in the nizable histone-binding domains and remains largely unexplored. context of breast cancer were next investigated. First, we com- Although one study speculated that KDM8 acts as a potential pared the expression of KDM8 in a panel of breast cancer cell tumor suppressor gene based on retrovirus insertional mutagen- lines to that of primary human mammary epithelial cells (HMECs) esis (8), no biological and molecular characterizations were de- by immunoblot analysis with a custom-generated rabbit polyclonal scribed in the report. We extensively examine and provide evidence that KDM8 possesses H3K36me2 demethylase activity and has the ability to Author contributions: D.A.H., M.R.P., H.-J.K., and Y.I. designed research; D.A.H., C.G.T., regulate cyclin A1 transcription in MCF7 breast cancer cells. We M.R.P., E.Y.C.H., C.I., S.B.H., and Y.I. performed research; D.A.H., E.Y.C.H., C.I., H.-W.C., and Y.I. contributed new reagents/analytic tools; D.A.H., C.G.T., M.R.P., M.E.W., H.-J.K., and found that KDM8 is recruited to cyclin A1 coding region bound Y.I. analyzed data; and D.A.H., C.G.T., H.-J.K., and Y.I. wrote the paper. H3K36me2 and demethylates this mark, resulting in increased The authors declare no conflict of interest. transcriptional activity. This finding is a departure from previous *This Direct Submission article had a prearranged editor. studies that showed that the majority of histone demethylases 1To whom correspondence may be addressed. E-mail: [email protected] or yizumiya@ exert their epigenetic effects at the promoters of genes. Addi- ucdavis.edu. tionally, we describe overexpression of KDM8 in breast cancer This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. tumors as well as its requirement for MCF7 cell cycle progression. 1073/pnas.1000401107/-/DCSupplemental. www.pnas.org/cgi/doi/10.1073/pnas.1000401107 PNAS | May 25, 2010 | vol. 107 | no. 21 | 9671–9676 Downloaded by guest on October 2, 2021 A B C D Fig. 1. KDM8 H3K36me2 demethylation in MCF7 breast cancer cells. (A) KDM8 and H321A, an inactive enzymatic mutant, were induced to express as Flag fusion proteins. Indirect immunofluorescence with antibodies against Flag (red staining) and methylated H3K36me1, H3K36me2, or H3K36me3 (green staining) was used to analyze in vivo substrate specificity of KDM8. DAPI staining (blue) indicates nuclei location in each field. Cells overexpressing KDM8 (arrows) showed significant loss of H3K36me2 staining, which was dependent on the active JmjC domain, and not observed in the H321A overexpressed cells. (B) Quantitative analysis of Dox-induced KDM8/H321A MCF7 H3K36me2 stained cells from 10 random fields. Eighty percent of induced KDM8 cells showed diminished H3K36me2, whereas 60% of H321A-induced cells exhibited increases in H3K36me2 staining. Percentage of cells that exhibited no change in H3K36me2 is not shown. (C) Histones extracted from Dox-induced KDM8/H321A MCF7 were analyzed by Western blotting with antibodies against H3K36me2 and H3K9me3. A decreased signal in H3K36me2 was observed in KDM8 overexpressed cells (lane 2 vs. lane 1), which was dependent on the active JmjC domain (inactive mutant lanes 3–4). (D) MS analysis of observed in vitro KDM8 demethylase activity. Reactions using H3K36me2 peptide combined with either GST KDM8 101-C WT or GST-KDM8 101-C H321A show 14 Da shift in WT reactions only (asterisk). antisera specific to KDM8. Although KDM8 protein expression indicated that 97.5% of the tumor samples were intensely stained was very low in HMECs, all of the breast cancer cell lines, including for KDM8 expression (i.e., 3+ score) compared with 67.5% in MCF7, exhibited significantly higher expression (Fig. 2A). To ex- normal patient-matched tissues (Fig. 2D). Both scoring systems tend our results, immunohistochemistry (IHC) was conducted (computerized and manual) concluded that KDM8 is overex- using a human tissue microarray containing 40 individual breast pressed in tumor tissues compared to their nonmalignant coun- cancer samples and patient-matched adjacent normal tissue con- terparts. To extend these results and determine if KDM8 trols (Fig. 2 B and C). Consistent with the results obtained in breast overexpression is potentially a general aberration occurring in cancer cell lines, KDM8 was widely overexpressed in breast cancer, a tumor array membrane consisting of spotted tumor tumors. IHC staining was quantified via computerized scanning and normal cell lysates was probed for KDM8 protein expression. analysis and manual scoring by an expert panel of pathologists Multiple types of tumors including thyroid, adrenal, bladder, who scored the IHC results on a scale from 0 through 3+, with 3+ uterine, and liver exhibited overexpressed KDM8 protein in indicating the most intense staining. The summarized IHC data comparison to their respective normal tissue controls (Fig. S2). 9672 | www.pnas.org/cgi/doi/10.1073/pnas.1000401107 Hsia et al.
Load more

Recommended publications
  • High-Throughput Discovery of Novel Developmental Phenotypes
    High-throughput discovery of novel developmental phenotypes The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Dickinson, M. E., A. M. Flenniken, X. Ji, L. Teboul, M. D. Wong, J. K. White, T. F. Meehan, et al. 2016. “High-throughput discovery of novel developmental phenotypes.” Nature 537 (7621): 508-514. doi:10.1038/nature19356. http://dx.doi.org/10.1038/nature19356. Published Version doi:10.1038/nature19356 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:32071918 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Nature. Manuscript Author Author manuscript; Manuscript Author available in PMC 2017 March 14. Published in final edited form as: Nature. 2016 September 22; 537(7621): 508–514. doi:10.1038/nature19356. High-throughput discovery of novel developmental phenotypes A full list of authors and affiliations appears at the end of the article. Abstract Approximately one third of all mammalian genes are essential for life. Phenotypes resulting from mouse knockouts of these genes have provided tremendous insight into gene function and congenital disorders. As part of the International Mouse Phenotyping Consortium effort to generate and phenotypically characterize 5000 knockout mouse lines, we have identified 410 Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms #Corresponding author: [email protected].
    [Show full text]
  • The Box C/D Snornp Assembly Factor Bcd1 Interacts with the Histone
    The box C/D snoRNP assembly factor Bcd1 interacts with the histone chaperone Rtt106 and controls its transcription dependent activity Benoît Bragantini, Christophe Charron, Maxime Bourguet, Arnaud Paul, Decebal Tiotiu, Benjamin Rothé, Hélène Marty, Guillaume Terral, Steve Hessmann, Laurence Decourty, et al. To cite this version: Benoît Bragantini, Christophe Charron, Maxime Bourguet, Arnaud Paul, Decebal Tiotiu, et al.. The box C/D snoRNP assembly factor Bcd1 interacts with the histone chaperone Rtt106 and controls its transcription dependent activity. Nature Communications, Nature Publishing Group, 2021, 12 (1), pp.1859. 10.1038/s41467-021-22077-4. hal-03181046 HAL Id: hal-03181046 https://hal.univ-lorraine.fr/hal-03181046 Submitted on 1 Apr 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution| 4.0 International License ARTICLE https://doi.org/10.1038/s41467-021-22077-4 OPEN The box C/D snoRNP assembly factor Bcd1 interacts with the histone chaperone Rtt106 and controls its transcription dependent
    [Show full text]
  • The Complexity of the Epigenome in Cancer and Recent Clinical Advances
    Published OnlineFirst August 17, 2012; DOI: 10.1158/1078-0432.CCR-12-2037 Clinical Cancer Molecular Pathways Research Molecular Pathways: The Complexity of the Epigenome in Cancer and Recent Clinical Advances Mariarosaria Conte1 and Lucia Altucci1,2 Abstract Human cancer is causally linked to genomic and epigenomic deregulations. Epigenetic abnormalities occurring within signaling pathways regulating proliferation, migration, growth, differentiation, tran- scription, and death signals may be critical in the progression of malignancies. Consequently, iden- tification of epigenetic marks and their bioimplications in tumors represents a crucial step toward defining new therapeutic strategies both in cancer treatment and prevention. Alterations of writers, readers, and erasers in cancer may affect, for example, the methylation and acetylation state of huge areas of chromatin, suggesting that epi-based treatments may require "distinct" therapeutic strategies com- pared with "canonical" targeted treatments. Whereas anticancer treatments targeting histone deacetylase and DNA methylation have entered the clinic, additional chromatin modification enzymes have not yet been pharmacologically targeted for clinical use in patients. Thus, a greater insight into alterations occurring on chromatin modifiers and their impact in tumorigenesis represents a crucial advance- ment in exploiting epigenetic targeting in cancer prevention and treatment. Here, the interplay of the best known epi-mutations and how their targeting might be optimized are addressed. Clin Cancer Res; 18 (20); 1–9. Ó2012 AACR. Background strategies both in cancer treatment and prevention (2). A number of epigenetic deregulations, such as DNA Alterations of writers, readers, and erasers in cancer may methylation, histone modifications, and microRNA-based affect the status of chromatin in vast areas of the epigenome, modulation, have been progressively reported as causally thus suggesting that epi-based treatments may require "dis- involved in tumorigenesis and progression.
    [Show full text]
  • Interspecific Variation in One-Carbon Metabolism Within The
    International Journal of Molecular Sciences Article Interspecific Variation in One-Carbon Metabolism within the Ovarian Follicle, Oocyte, and Preimplantation Embryo: Consequences for Epigenetic Programming of DNA Methylation Constance E. Clare 1,†, Valerie Pestinger 1,†, Wing Yee Kwong 1,†, Desmond A. R. Tutt 1, Juan Xu 1,2, Helen M. Byrne 3, David A. Barrett 2, Richard D. Emes 1 and Kevin D. Sinclair 1,* 1 Schools of Biosciences and Veterinary Medicine and Science, University of Nottingham, Sutton Bonington, Leicestershire LE12 5RD, UK; [email protected] (C.E.C.); [email protected] (V.P.); [email protected] (W.Y.K.); [email protected] (D.A.R.T.); [email protected] (J.X.); [email protected] (R.D.E.) 2 Centre for Analytical Bioscience, School of Pharmacy, University of Nottingham, Nottingham NG7 2RD, UK; [email protected] 3 Mathematical Institute, University of Oxford, Woodstock Road, Oxford OX2 6GG, UK; [email protected] * Correspondence: [email protected]; Tel.: +44-0-115-951-6053 † These authors contributed equally to this work. Abstract: One-carbon (1C) metabolism provides methyl groups for the synthesis and/or methylation Citation: Clare, C.E.; Pestinger, V.; Kwong, W.Y.; Tutt, D.A.R.; Xu, J.; of purines and pyrimidines, biogenic amines, proteins, and phospholipids. Our understanding of Byrne, H.M.; Barrett, D.A.; Emes, how 1C pathways operate, however, pertains mostly to the (rat) liver. Here we report that transcripts R.D.; Sinclair, K.D. Interspecific for all bar two genes (i.e., BHMT, MAT1A) encoding enzymes in the linked methionine-folate cycles Variation in One-Carbon Metabolism are expressed in all cell types within the ovarian follicle, oocyte, and blastocyst in the cow, sheep, within the Ovarian Follicle, Oocyte, and pig; as well as in rat granulosa cells (GCs) and human KGN cells (a granulosa-like tumor cell and Preimplantation Embryo: line).
    [Show full text]
  • Mutations in the PKM2 Exon-10 Region Are Associated with Reduced Allostery and Increased Nuclear Translocation
    ARTICLE https://doi.org/10.1038/s42003-019-0343-4 OPEN Mutations in the PKM2 exon-10 region are associated with reduced allostery and increased nuclear translocation Tsan-Jan Chen 1, Hung-Jung Wang2, Jai-Shin Liu1, Hsin-Hung Cheng1, Sheng-Chieh Hsu2,3, Meng-Chen Wu1, 1234567890():,; Chien-Hung Lu1, Yu-Fang Wu1, Jing-Wen Wu1, Ying-Yuan Liu1, Hsing-Jien Kung4,5 & Wen-Ching Wang1 PKM2 is a key metabolic enzyme central to glucose metabolism and energy expenditure. Multiple stimuli regulate PKM2’s activity through allosteric modulation and post-translational modifications. Furthermore, PKM2 can partner with KDM8, an oncogenic demethylase and enter the nucleus to serve as a HIF1α co-activator. Yet, the mechanistic basis of the exon-10 region in allosteric regulation and nuclear translocation remains unclear. Here, we determined the crystal structures and kinetic coupling constants of exon-10 tumor-related mutants (H391Y and R399E), showing altered structural plasticity and reduced allostery. Immunoprecipitation analysis revealed increased interaction with KDM8 for H391Y, R399E, and G415R. We also found a higher degree of HIF1α-mediated transactivation activity, particularly in the presence of KDM8. Furthermore, overexpression of PKM2 mutants significantly elevated cell growth and migration. Together, PKM2 exon-10 mutations lead to structure-allostery alterations and increased nuclear functions mediated by KDM8 in breast cancer cells. Targeting the PKM2-KDM8 complex may provide a potential therapeutic intervention. 1 Institute of Molecular and Cellular Biology and Department of Life Science, National Tsing-Hua University, Hsinchu 30013, Taiwan. 2 Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli 35053, Taiwan.
    [Show full text]
  • Design, Synthesis and Biological Evaluation of Small Molecules As Modulators of Histone Methyltransferases and Demethylases
    PhD School of Pharmaceutical Sciences XXVI cycle University of Naples “Federico II” DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF SMALL MOLECULES AS MODULATORS OF HISTONE METHYLTRANSFERASES AND DEMETHYLASES Doctoral Candidate: Supervisor: Stefano Tomassi Prof. Ettore Novellino Department of Pharmacy Faculty of Pharmacy University of Naples “Federico II” Supervisors Professor Ettore Novellino Ph.D. (tutor and main supervisor) Department of Pharmacy, University of Naples “Federico II”, Via Domenico Montesano, 49 - 80131 Naples, Italy. Adjunct Professor Antonello Mai Ph.D. (external supervisor) Department of Drug Chemistry and Technology, “Sapienza” University of Rome, P.le Aldo Moro, 5 - 00185 - Rome, Italy. 2 Table of contents 1. INTRODUCTION ................................................................................................. 5 2. EPIGENETIC AND CHROMATIN DYNAMICS ............................................ 8 3. HISTONE METHYLATION ............................................................................. 11 3.1 Protein Arginine Methyltransferases (PRMTs) .......................................... 12 3.2 Histone Lysine Methyltransferases (HKMTs) ............................................ 21 3.2.1 Enhancer of Zeste Homologue 2 (EZH2) .............................................. 27 3.2.2 EZH2 aberrations and cancer ................................................................ 36 3.3 Targeting Histone Arginine and Lysine Methyltransferases .................... 39 4. DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF NOVEL
    [Show full text]
  • JMJD-5/KDM8 Regulates H3k36me2 and Is Required for Late Steps of Homologous Recombination and Genome Integrity
    JMJD-5/KDM8 regulates H3K36me2 and is required for late steps of homologous recombination and genome integrity Amendola, Pier Giorgio; Zaghet, Nico; Ramalho, João J; Johansen, Jens Vilstrup; Boxem, Mike; Salcini, Anna Elisabetta Published in: P L o S Genetics DOI: 10.1371/journal.pgen.1006632 Publication date: 2017 Document version Publisher's PDF, also known as Version of record Document license: CC BY Citation for published version (APA): Amendola, P. G., Zaghet, N., Ramalho, J. J., Johansen, J. V., Boxem, M., & Salcini, A. E. (2017). JMJD-5/KDM8 regulates H3K36me2 and is required for late steps of homologous recombination and genome integrity. P L o S Genetics, 13(2), [e1006632]. https://doi.org/10.1371/journal.pgen.1006632 Download date: 29. sep.. 2021 RESEARCH ARTICLE JMJD-5/KDM8 regulates H3K36me2 and is required for late steps of homologous recombination and genome integrity Pier Giorgio Amendola1,2, Nico Zaghet1,2, João J. Ramalho3, Jens Vilstrup Johansen1,2, Mike Boxem3, Anna Elisabetta Salcini1,2* 1 Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark, 2 Centre for Epigenetics, University of Copenhagen, Copenhagen, Denmark, 3 Developmental Biology, Department of Biology, Faculty of Science, Utrecht University, Padualaan 8, CH Utrecht, The Netherlands a1111111111 a1111111111 * [email protected] a1111111111 a1111111111 a1111111111 Abstract The eukaryotic genome is organized in a three-dimensional structure called chromatin, con- stituted by DNA and associated proteins, the majority of which are histones. Post-transla- OPEN ACCESS tional modifications of histone proteins greatly influence chromatin structure and regulate Citation: Amendola PG, Zaghet N, Ramalho JJ, many DNA-based biological processes.
    [Show full text]
  • The Changing Chromatome As a Driver of Disease: a Panoramic View from Different Methodologies
    The changing chromatome as a driver of disease: A panoramic view from different methodologies Isabel Espejo1, Luciano Di Croce,1,2,3 and Sergi Aranda1 1. Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology, Dr. Aiguader 88, Barcelona 08003, Spain 2. Universitat Pompeu Fabra (UPF), Barcelona, Spain 3. ICREA, Pg. Lluis Companys 23, Barcelona 08010, Spain *Corresponding authors: Luciano Di Croce ([email protected]) Sergi Aranda ([email protected]) 1 GRAPHICAL ABSTRACT Chromatin-bound proteins regulate gene expression, replicate and repair DNA, and transmit epigenetic information. Several human diseases are highly influenced by alterations in the chromatin- bound proteome. Thus, biochemical approaches for the systematic characterization of the chromatome could contribute to identifying new regulators of cellular functionality, including those that are relevant to human disorders. 2 SUMMARY Chromatin-bound proteins underlie several fundamental cellular functions, such as control of gene expression and the faithful transmission of genetic and epigenetic information. Components of the chromatin proteome (the “chromatome”) are essential in human life, and mutations in chromatin-bound proteins are frequently drivers of human diseases, such as cancer. Proteomic characterization of chromatin and de novo identification of chromatin interactors could thus reveal important and perhaps unexpected players implicated in human physiology and disease. Recently, intensive research efforts have focused on developing strategies to characterize the chromatome composition. In this review, we provide an overview of the dynamic composition of the chromatome, highlight the importance of its alterations as a driving force in human disease (and particularly in cancer), and discuss the different approaches to systematically characterize the chromatin-bound proteome in a global manner.
    [Show full text]
  • Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen
    cancers Article Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen Juho J. Miettinen 1,† , Romika Kumari 1,†, Gunnhildur Asta Traustadottir 2 , Maiju-Emilia Huppunen 1, Philipp Sergeev 1, Muntasir M. Majumder 1, Alexander Schepsky 2 , Thorarinn Gudjonsson 2 , Juha Lievonen 3, Despina Bazou 4, Paul Dowling 5, Peter O‘Gorman 4, Ana Slipicevic 6, Pekka Anttila 3, Raija Silvennoinen 3 , Nina N. Nupponen 6, Fredrik Lehmann 6 and Caroline A. Heckman 1,* 1 Institute for Molecular Medicine Finland-FIMM, HiLIFE–Helsinki Institute of Life Science, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, 00290 Helsinki, Finland; juho.miettinen@helsinki.fi (J.J.M.); romika.kumari@helsinki.fi (R.K.); maiju-emilia.huppunen@helsinki.fi (M.-E.H.); philipp.sergeev@helsinki.fi (P.S.); muntasir.mamun@helsinki.fi (M.M.M.) 2 Stem Cell Research Unit, Biomedical Center, University of Iceland, 101 Reykjavik, Iceland; [email protected] (G.A.T.); [email protected] (A.S.); [email protected] (T.G.) 3 Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, 00290 Helsinki, Finland; juha.lievonen@hus.fi (J.L.); pekka.anttila@hus.fi (P.A.); raija.silvennoinen@helsinki.fi (R.S.) 4 Department of Hematology, Mater Misericordiae University Hospital, D07 Dublin, Ireland; [email protected] (D.B.); [email protected] (P.O.) 5 Department of Biology, Maynooth University, National University of Ireland, Citation: Miettinen, J.J.; Kumari, R.; W23 F2H6 Maynooth, Co. Kildare, Ireland; [email protected] Traustadottir, G.A.; Huppunen, M.-E.; 6 Oncopeptides AB, 111 53 Stockholm, Sweden; [email protected] (A.S.); Sergeev, P.; Majumder, M.M.; [email protected] (N.N.N.); [email protected] (F.L.) Schepsky, A.; Gudjonsson, T.; * Correspondence: caroline.heckman@helsinki.fi; Tel.: +358-50-415-6769 † These authors equally contributed to this work.
    [Show full text]
  • KDM8 Antibody Order 021-34695924 [email protected] Support 400-6123-828 50Ul [email protected] 100 Ul √ √ Web
    TD12535 KDM8 Antibody Order 021-34695924 [email protected] Support 400-6123-828 50ul [email protected] 100 uL √ √ Web www.ab-mart.com.cn Description: Bifunctional enzyme that acts both as an endopeptidase and 2-oxoglutarate-dependent monoxygenase. Endopeptidase that cleaves histones N-terminal tails at the carboxyl side of methylated arginine or lysine residues, to generate 'tailless nucleosomes', which may trigger transcription elongation. Preferentially recognizes and cleaves monomethylated and dimethylated arginine residues of histones H2, H3 and H4. After initial cleavage, continues to digest histones tails via its aminopeptidase activity. Upon DNA damage, cleaves the N- terminal tail of histone H3 at monomethylated lysine residues, preferably at monomethylated 'Lys-9' (H3K9me1). The histone variant H3F3A is the major target for cleavage. Additionnally, acts as Fe(2+) and 2-oxoglutarate-dependent monoxygenase, catalyzing (R)-stereospecific hydroxylation at C-3 of 'Arg-137' of RPS6 and 'Arg-141' of RCCD1, but the biological significance of this activity remains to be established. Regulates mitosis through different mechanisms: Plays a role in transcriptional repression of satellite repeats, possibly by regulating H3K36 methylation levels in centromeric regions together with RCCD1. Possibly together with RCCD1, is involved in proper mitotic spindle organization and chromosome segregation. Negatively regulates cell cycle repressor CDKN1A/p21, which controls G1/S phase transition. Required for G2/M phase cell cycle progression. Regulates expression of CCNA1/cyclin-A1, leading to cancer cell proliferation. Also, plays a role in regulating alpha-tubulin acetylation and cytoskeletal microtubule stability involved in epithelial to mesenchymal transition. Regulates the circadian gene expression in the liver (By similarity).
    [Show full text]
  • Analysis of Mammalian Gene Function Through Broad-Based Phenotypic
    ARTICLES Analysis of mammalian gene function through broad-based phenotypic screens across a consortium of mouse clinics The function of the majority of genes in the mouse and human genomes remains unknown. The mouse embryonic stem cell knockout resource provides a basis for the characterization of relationships between genes and phenotypes. The EUMODIC consortium developed and validated robust methodologies for the broad-based phenotyping of knockouts through a pipeline comprising 20 disease-oriented platforms. We developed new statistical methods for pipeline design and data analysis aimed at detecting reproducible phenotypes with high power. We acquired phenotype data from 449 mutant alleles, representing 320 unique genes, of which half had no previous functional annotation. We captured data from over 27,000 mice, finding that 83% of the mutant lines are phenodeviant, with 65% demonstrating pleiotropy. Surprisingly, we found significant differences in phenotype annotation according to zygosity. New phenotypes were uncovered for many genes with previously unknown function, providing a powerful basis for hypothesis generation and further investigation in diverse systems. Phenotypic annotations of knockout mutants have been generated for (EMPReSS) database10 catalogs the standard operating procedures about a third of the genes in the mouse genome1. However, the way in (SOPs) that were developed, including operational details and the which the phenotype is screened is often dependent on the expertise and parameters measured. More recently, a major single-center effort interests of the investigator, and in only a few cases has a broad-based to analyze several hundred knockout lines through a phenotyping assessment of phenotype been undertaken that encompassed the analy- pipeline has illuminated the pleiotropy that can be found and the sis of developmental, biochemical, physiological and organ systems2–4.
    [Show full text]
  • KDM8/JMJD5 As a Dual Coactivator of AR and PKM2 Integrates AR/EZH2 Network and Tumor Metabolism in CRPC
    Oncogene (2019) 38:17–32 https://doi.org/10.1038/s41388-018-0414-x ARTICLE KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC 1,2 3 3 3 2 1,4 Hung-Jung Wang ● Mamata Pochampalli ● Ling-Yu Wang ● June X Zou ● Pei-Shan Li ● Sheng-Chieh Hsu ● 5 5 6,7 6 8 8 Bi-Juan Wang ● Shih-Han Huang ● Ping Yang ● Joy C. Yang ● Cheng-Ying Chu ● Chia-Ling Hsieh ● 8 9 6 8,10 1,6 Shian-Ying Sung ● Chien-Feng Li ● Clifford G. Tepper ● David K. Ann ● Allen C. Gao ● 6,11 11 5 12 3,11 Christopher P. Evans ● Yoshihiro Izumiya ● Chi-Pin Chuu ● Wen-Ching Wang ● Hong-Wu Chen ● Hsing-Jien Kung2,3,4,8 Received: 2 November 2017 / Revised: 19 May 2018 / Accepted: 21 June 2018 / Published online: 2 August 2018 © The Author(s) 2018. This article is published with open access Abstract During the evolution into castration or therapy resistance, prostate cancer cells reprogram the androgen responses to cope with the diminishing level of androgens, and undergo metabolic adaption to the nutritionally deprived and hypoxia conditions. AR (androgen receptor) and PKM2 (pyruvate kinase M2) have key roles in these processes. We report in this 1234567890();,: 1234567890();,: study, KDM8/JMJD5, a histone lysine demethylase/dioxygnase, exhibits a novel property as a dual coactivator of AR and PKM2 and as such, it is a potent inducer of castration and therapy resistance. Previously, we showed that KDM8 is involved in the regulation of cell cycle and tumor metabolism in breast cancer cells.
    [Show full text]